Medline (MDLN): Scale and Retention Support a Buy

Thesis

Medline (MDLN) looks like a solid but not cheap compounder for a balanced, moderate-risk investor. The core case rests on three hard facts. First, the business is growing at scale: FY2025 net sales reached $28.4B, up 11.5%, and Q1 2026 net sales rose another 10.7% to $7.4B. Second, the model has real operating depth: Medline Brand produced $13.7B of FY2025 sales and Supply Chain Solutions produced $14.7B, supported by 30 manufacturing facilities, 600+ global sourcing partners, and 45 distribution centers serving 95% of U.S. customers with next-day delivery. Third, customer stickiness is unusually strong, with >98% average Prime Vendor retention over the past five years and $2.4B of new customer signings in 2025.

The catch is margin quality. FY2025 adjusted EBITDA increased just 3.2% to $3.5B while sales grew 11.5%, and Q4 2025 adjusted EBITDA slipped 0.6% to $805M despite 14.8% sales growth because tariffs and higher operating costs ate into the benefit of volume. The same pattern showed up in reported results: FY2025 revenue increased to $28.43B from $25.51B, but net income edged down to $1.16B from $1.20B, and quarterly net income fell to $180M in Q4 2025 from $322M in Q3 2025. This is a good business with a little sand in the gears.

That leaves MDLN in a middle lane. The company has the scale, retention, and infrastructure to keep taking share in a large med-surg market, but the stock already reflects much of that quality with a trailing P/E of 31.7 and forward P/E of 30.3. With analyst targets clustered around the low-$50s and one internal consensus snapshot at $53.52, the stock does not screen as a bargain. The medium-term setup supports a Buy on pullbacks rather than an aggressive chase at any price, with fair value anchored at $49.

Company Overview

Medline is a U.S.-based healthcare supplies company listed on Nasdaq as MDLN. It operates in Health Care Equipment & Supplies and manufactures and distributes medical-surgical products across hospitals, surgery centers, physician offices, post-acute facilities, nursing homes, and international markets. The company was founded in 1966, is headquartered in Northfield, Illinois, and employs about 45,000 people.

The business is organized into two segments: Medline Brand and Supply Chain Solutions. Medline Brand includes internally manufactured and sourced products across surgical solutions, front line care, and laboratory and diagnostics. Supply Chain Solutions distributes third-party national brands and provides logistics, consulting, inventory rationalization, outsourced warehouse management, route planning, and related services. In plain English, Medline is not just selling boxes of gloves and drapes. It is trying to become the operating system behind how providers buy, stock, and move those boxes.

The company came public on 2025-12-17. That matters because recent financials still carry the fingerprints of IPO-related costs and ownership transitions. It also matters because the public market is still figuring out what multiple to assign a business that sits somewhere between a manufacturer, a distributor, and a healthcare workflow platform.

Business Segment Deep Dive

Medline Brand generated $13.7B of FY2025 net sales, up 9.6% YoY, and produced $3.3B of segment adjusted EBITDA, up 2.0%. That means the segment represented 48% of revenue but 81% of segment adjusted EBITDA. This is the economic engine. The segment includes higher-value private-label and internally produced categories where Medline has more control over product mix, sourcing, and margin.

Within Medline Brand, Surgical Solutions was the fastest-growing sub-segment in FY2025 with 12.7% net sales growth, helped by higher volume in kitting and operating room products and the Ecolab Surgical Solutions acquisition. Front Line Care grew 7.0%, supported by demand across multiple product divisions and the Coloplast skincare acquisition. Lab & Diagnostics grew 8.8% on volume growth from existing and new customers. Those are healthy numbers, but the EBITDA growth lag tells the real story: volume is strong, cost capture is slower.

Supply Chain Solutions generated $14.7B of FY2025 net sales, up 13.2%, and $805M of segment adjusted EBITDA, up 24.4%. That is a notable contrast. The segment represented 52% of revenue but only 19% of segment adjusted EBITDA, yet it delivered faster EBITDA growth than Medline Brand. In Q4 2025, Supply Chain Solutions sales rose 17.6% to $4.1B and adjusted EBITDA jumped 29.2% to $217M. Growth was driven by Prime Vendor sales, including new customer implementations and expansion with existing customers.

The segment mix matters for investors. Medline Brand carries the richer economics, while Supply Chain Solutions deepens customer relationships and expands route density. One segment is the margin anchor, the other is the moat builder. Together they create a model that is harder to dislodge than a pure distributor and more scalable than a narrow product manufacturer.

Flagship Product Analysis

Medline does not depend on a single blockbuster product in the way a device maker or drug company might. Its flagship strength is the breadth of its med-surg portfolio and the way that portfolio plugs into provider workflows. The company says it has about 335,000 products, including about 190,000 Medline Brand items, and manufactures roughly 70,000 med-surg and lab products across 30 global manufacturing facilities.

The strongest product cluster appears to be Surgical Solutions. FY2025 Surgical Solutions sales growth of 12.7% outpaced Front Line Care at 7.0% and Lab & Diagnostics at 8.8%. Management tied that growth to kitting and operating room products, plus the Ecolab Surgical Solutions acquisition. Kitting matters because it turns a commodity basket into a workflow solution. Hospitals do not just buy components. They buy time, standardization, and fewer errors. That is where pricing gets less fragile.

Front Line Care remains important because it covers recurring patient-facing needs such as wound care, exam gloves, skin care, incontinence products, cleaning supplies, textiles, hand sanitizer, durable medical equipment, and infection control products. These are not glamorous categories, but they are habitual spend categories. In healthcare, boring can be beautiful if it repeats often enough.

Lab & Diagnostics adds another layer of stickiness through analyzers, point-of-care testing, consumables, and monitoring products. The segment’s 8.8% FY2025 growth, driven by existing and new customers, shows that Medline is not just defending legacy categories. It is broadening its relevance inside the clinical workflow.

Innovation & Competitive Advantage

Medline’s competitive edge comes from scale, vertical integration, customer lock-in, and technology. The company manufactures about one-third of Medline Brand products in 30 facilities, sources the rest through 600+ global partners across about 40 countries, and maintains 300+ exclusive relationships. That gives it more levers than a distributor that simply buys and resells inventory.

The logistics footprint is equally important. Medline operates 45 distribution centers with more than 26M square feet of warehouse space and says it can reach 95% of U.S. customers with next-day delivery. In supply chain businesses, density is destiny. More customers mean fuller routes, fuller routes mean lower unit cost, and lower unit cost helps win more customers. It is a flywheel, not a slogan.

Technology is becoming a more visible differentiator. Medline launched Mpower, an AI-enabled digital supply chain control tower built with Microsoft. The company said early users saw >50% efficiency gains in substitution workflows and 1% to 2% higher unadjusted fill rates when paired with AutoSub. Those are not moonshot claims about reinventing healthcare. They are practical workflow gains, which is usually where durable software value hides.

The company is also expanding robotic automation in U.S. distribution centers. That should support resiliency and labor productivity over time. Combined with Prime Vendor contracts that typically run five years and retention above 98% over the past five years, the result is a moat built less on patent drama and more on operational entanglement. Customers do not switch these systems casually because the real product is continuity.

Operations & Supply Chain

Medline’s operations are a central part of the investment case. The company combines internal manufacturing, global sourcing, and national distribution in a single platform. About one-third of Medline Brand products are manufactured internally, while the remainder are sourced from 600+ partners across around 40 countries. That mix gives Medline flexibility, but it also exposes the company to tariff and input-cost pressure, which showed up clearly in 2025 and Q1 2026.

The distribution network is large by any standard: 45 distribution centers, more than 26M square feet of warehouse capacity, and an owned fleet. Management says this network supports next-day delivery to 95% of U.S. customers. That service level matters in healthcare because stockouts are not just inconvenient. They can disrupt procedures, staffing, and patient care. Reliability becomes part of the sales pitch.

Operational execution also shows up in customer wins. Medline reported $2.4B of total new customer signings in FY2025, including several large IDNs, partnerships with the U.S. Department of Veterans Affairs, and one of the largest faith-based IDNs in the U.S. New implementations were cited as a driver of both FY2025 and Q1 2026 growth. That is a strong sign that the network is not just large, but commercially productive.

The weak spot is cost inflation. FY2025 adjusted EBITDA rose only 3.2% to $3.5B despite 11.5% sales growth, and Q4 2025 adjusted EBITDA fell 0.6% to $805M despite 14.8% sales growth. Management attributed the pressure to higher COGS from tariffs and higher operating costs, including headcount investments. The machine is clearly moving volume. The question is how much of that volume converts into cleaner incremental profit.

Market Analysis

Medline operates in a large and fragmented market. The company’s own framing puts total addressable market at about $375B globally, split between roughly $175B in the U.S. and $200B internationally. That is a useful anchor because Medline generated $28.4B of FY2025 sales, which implies meaningful room for share gains even without heroic assumptions.

Third-party market estimates also support a large runway, even if the exact scope varies. Mordor Intelligence estimates the global medical supplies market at $180.2B in 2025, rising to $318.77B by 2031, implying 9.97% CAGR from 2026 to 2031. Its narrower hospital supplies market estimate points to 3.99% CAGR over the same period. The spread between those figures says more about category definitions than about demand quality. The broad message is that med-surg remains a large, durable market with growth extending beyond hospitals into home care, ambulatory settings, and other alternate sites.

That shift in care settings fits Medline’s footprint. In FY2025, U.S. Acute sales were $19.5B, U.S. Non-acute sales were $7.0B, and International sales were $2.0B. The acute business is still the heavyweight, but the non-acute and international channels offer room for expansion. Home care is projected by Mordor to be the fastest-growing channel in medical supplies, and ambulatory surgical centers are forecast to grow faster than hospitals in hospital supplies. Medline already sells into those settings, which gives it a practical way to follow care migration rather than fight it.

The market backdrop also favors suppliers that can offer total cost of ownership improvements rather than just low unit prices. Procurement teams increasingly care about fill rates, standardization, workflow efficiency, and resilience. That lines up with Medline’s Prime Vendor and digital supply chain pitch. In other words, the industry is moving toward exactly the kind of bundle Medline wants to sell.

Customer Profile

Medline serves a wide customer base across hospitals, surgery centers, physician offices, post-acute facilities, nursing homes, and international providers. The FY2025 channel mix shows the center of gravity clearly: U.S. Acute at $19.5B, U.S. Non-acute at $7.0B, and International at $2.0B. This is still primarily a U.S. hospital and health-system story, but not exclusively so.

The most important customer relationship structure is the Prime Vendor model. These agreements typically run five years and position Medline as the primary consolidated logistics partner for med-surg needs. The company says it has maintained >98% average Prime Vendor retention over the past five years and has signed new Prime Vendor contracts representing about $8B of annual contract value over the past six years. That is a strong sign of embedded customer relationships and high switching friction.

Customer wins in 2025 reinforce the point. Medline reported $2.4B of total new customer signings, including large IDNs, strategic partnerships with the VA, and a major faith-based IDN. Those wins matter because large systems tend to buy not just product, but service reliability, implementation capability, and procurement integration. Once Medline is inside the workflow, the relationship gets harder to unwind.

For investors, the customer profile cuts both ways. The stickiness is attractive, but concentration risk is real. Losing a major health system contract would hurt volume and route density. In a business built on logistics scale, one lost whale can ripple across the pond.

Competitive Landscape

Medline competes against Owens & Minor, Cardinal Health, McKesson Medical-Surgical, and Henry Schein, along with regional distributors and self-distribution models. The company describes itself as the largest provider of medical-surgical products and supply chain solutions serving all points of care. That leadership claim is supported by its scale, product breadth, and integrated manufacturing-plus-distribution model.

Relative to Cardinal Health and McKesson, Medline is more focused on med-surg and supply chain solutions rather than broader pharma distribution. That narrower focus can be an advantage in specialization, though it also means less diversification. Relative to Owens & Minor, Medline appears larger and more vertically integrated. Relative to Henry Schein, Medline is stronger in acute-care and hospital med-surg, while Henry Schein remains more concentrated in dental and physician-office channels.

The strongest competitive differentiators are breadth and integration. Medline says it has about 335,000 products, including about 190,000 Medline Brand items, and manufactures roughly 70,000 products across 30 facilities. Pair that with 45 distribution centers and a 95% next-day U.S. delivery footprint, and the company starts to look less like a catalog seller and more like a national infrastructure asset.

The risk is that many categories remain commoditized. Procurement teams are ruthless when products look interchangeable, and larger customers have bargaining power. That is why Medline’s ability to bundle products with logistics, technology, and workflow support matters so much. It is trying to compete on total value, not just on the price tag attached to a case of gloves.

Macro & Geopolitical Landscape

The macro backdrop for Medline is mixed but manageable. On the positive side, healthcare supply demand tends to be steadier than most industrial end markets, and CMS projections cited by the company point to 5.6% CAGR in U.S. national health expenditures from 2023 to 2032. Aging populations, chronic disease, and the shift toward outpatient and home-based care all support long-term demand for med-surg consumables.

The pressure point is trade and input costs. Medline explicitly said FY2025 EBITDA was held back by higher COGS due to tariffs, and Q1 2026 GAAP diluted EPS of $0.16 trailed adjusted diluted EPS of $0.33 because of tariff-related cost pressure, IPO-related expenses, and other non-core items. This is the kind of business where tariffs do not arrive with fireworks. They show up quietly in gross margin and stay longer than investors would like.

Management said it does not expect any impact on full-year 2026 guidance from recent Section 232 tariff changes or the Middle East conflict. That is helpful, but the recent record already shows that tariffs can pressure profitability even when revenue remains strong. Investors should treat geopolitical risk here as a margin issue more than a demand issue.

Healthcare providers are also under reimbursement, labor, and inflation pressure, which pushes them to simplify vendors and seek total cost savings. That can help Medline win share as a scaled partner, but it can also intensify pricing pressure. In short, the macro environment favors reliable operators, but it does not hand them easy margins.

Balance Sheet Health

Income Statement Strength

Estimates Outlook

Valuation Assessment

Target Prices & Recommendation

Closing

Medline is a serious company with a serious moat. FY2025 sales of $28.4B, Q1 2026 sales growth of 10.7%, >98% Prime Vendor retention, 45 distribution centers, and a broad product portfolio all point to a business that is built to endure. The company is taking share, deepening customer relationships, and investing in automation and digital tools that should strengthen the model over time.

What keeps the report from turning more aggressive is not demand. It is conversion. Tariffs, higher operating costs, and a leveraged balance sheet have made the earnings story less elegant than the revenue story. Investors do not need perfection here, but they do need discipline on entry price.

For a medium-term investor, MDLN earns a Buy, with fair value anchored at $49. That view respects both sides of the ledger: a high-quality healthcare supplies platform with durable share-gain potential, and a stock that still needs to prove it can turn that strength into cleaner margin expansion. In markets, as in medicine, dosage matters. Medline is worth owning, just not at any price.